- Home
- ABVC vs ELEV Comparison
ABVC vs ELEV Comparison
Compare ABVC & ELEV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABVC
- ELEV
- Stock Information
- Founded
- ABVC 2015
- ELEV 2019
- Country
- ABVC United States
- ELEV United States
- Employees
- ABVC N/A
- ELEV N/A
- Industry
- ABVC Biotechnology: Pharmaceutical Preparations
- ELEV Biotechnology: Pharmaceutical Preparations
- Sector
- ABVC Health Care
- ELEV Health Care
- Exchange
- ABVC Nasdaq
- ELEV Nasdaq
- Market Cap
- ABVC 22.1M
- ELEV 22.8M
- IPO Year
- ABVC N/A
- ELEV 2021
- Fundamental
- Price
- ABVC $2.19
- ELEV $0.39
- Analyst Decision
- ABVC
- ELEV Hold
- Analyst Count
- ABVC 0
- ELEV 6
- Target Price
- ABVC N/A
- ELEV $1.77
- AVG Volume (30 Days)
- ABVC 312.1K
- ELEV 2.0M
- Earning Date
- ABVC 08-13-2025
- ELEV 08-05-2025
- Dividend Yield
- ABVC N/A
- ELEV N/A
- EPS Growth
- ABVC N/A
- ELEV N/A
- EPS
- ABVC N/A
- ELEV N/A
- Revenue
- ABVC $508,383.00
- ELEV N/A
- Revenue This Year
- ABVC $735.18
- ELEV N/A
- Revenue Next Year
- ABVC N/A
- ELEV N/A
- P/E Ratio
- ABVC N/A
- ELEV N/A
- Revenue Growth
- ABVC 1904.43
- ELEV N/A
- 52 Week Low
- ABVC $0.40
- ELEV $0.22
- 52 Week High
- ABVC $2.29
- ELEV $3.28
- Technical
- Relative Strength Index (RSI)
- ABVC 70.75
- ELEV 62.35
- Support Level
- ABVC $1.84
- ELEV $0.38
- Resistance Level
- ABVC $2.29
- ELEV $0.39
- Average True Range (ATR)
- ABVC 0.16
- ELEV 0.01
- MACD
- ABVC 0.03
- ELEV 0.00
- Stochastic Oscillator
- ABVC 87.65
- ELEV 85.00
About ABVC ABVC BioPharma Inc.
ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development. Its drug products focus on utilizing its licensed technology to conduct proof-of-concept trials through Phase II of the clinical development process. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes.
About ELEV Elevation Oncology Inc. Common stock
Elevation Oncology Inc is an oncology company focused on the development of selective cancer therapies to treat patients across a range of solid tumors with unmet medical needs. Its product candidate, EO-3021 (also known as SYSA1801 or CPO102), is an ADC comprised of a fully human anti-Claudin 18.2 immunoglobulin G1 (IgG1) monoclonal antibody (mAb) site-specifically conjugated with a cleavable linker to the cytotoxic monomethyl auristatin E (MMAE) payload. Claudin 18.2 is overexpressed in several types of cancers, including gastric, esophageal, pancreatic, ovarian and lungon.